Abstract
It appears that selective Cox-2 inhibitors do not affect the gastro duodenal mucosa whilst having antiinflammatory and analgesic efficacy similar to non-selective NSAIDs. Two broad categories of drugs are Cox-2 selective: coxibs and a number of pre-existing NSAIDs retrospectively found to have selectivity. Cox-2 inhibitors cause less dyspepsia than NSAIDs. They spare gastrointestinal mucosal generation of prostaglandins (PGs) and PGdependant bicarbonate secretion. Coxibs cause no acute mucosal injury in endoscopic studies and serendipitous Cox-2 inhibitors generally cause less acute injury than non -selective NSAIDs or placebo. Both celecoxib and rofecoxib have been associated with a substantial reduction in endoscopic ulcers compared to NSAID comparators. In the VIGOR study all upper GI events were reduced from 4.5 per 100 patient years to 2.1 per 100 patient years with supra-therapeutic doses of rofecoxib compared with naproxen. In the CLASS study, over a period of 3 days to 6 months, incidence of ulcer complications was 0.76% with celecoxib and 1.45% for ibuprofen or diclofenac. The less substantial reduction in events in the CLASS study compared with the VIGOR may be due, at least in part, to the fact that 21% of the patients were also on low dose aspirin. However it is premature to say that the benefit of Cox-2 inhibitors is lost in patients taking aspirin. There is continuing debate on the role of Cox-2 inhibitors in patients who have other risk factors for complicated ulcer disease e.g. patients who are elderly, on aspirin or corticosteroids, have a previous ulcer or have H. pylori infection.
Keywords: gastrointestinal safety, cox-2 inhibitor, rofecoxib, nsaid toxicity
Current Pharmaceutical Design
Title: Gastrointestinal Safety of Selective COX-2 Inhibitors
Volume: 8 Issue: 12
Author(s): C. J. Hawkey and M. M. Skelly
Affiliation:
Keywords: gastrointestinal safety, cox-2 inhibitor, rofecoxib, nsaid toxicity
Abstract: It appears that selective Cox-2 inhibitors do not affect the gastro duodenal mucosa whilst having antiinflammatory and analgesic efficacy similar to non-selective NSAIDs. Two broad categories of drugs are Cox-2 selective: coxibs and a number of pre-existing NSAIDs retrospectively found to have selectivity. Cox-2 inhibitors cause less dyspepsia than NSAIDs. They spare gastrointestinal mucosal generation of prostaglandins (PGs) and PGdependant bicarbonate secretion. Coxibs cause no acute mucosal injury in endoscopic studies and serendipitous Cox-2 inhibitors generally cause less acute injury than non -selective NSAIDs or placebo. Both celecoxib and rofecoxib have been associated with a substantial reduction in endoscopic ulcers compared to NSAID comparators. In the VIGOR study all upper GI events were reduced from 4.5 per 100 patient years to 2.1 per 100 patient years with supra-therapeutic doses of rofecoxib compared with naproxen. In the CLASS study, over a period of 3 days to 6 months, incidence of ulcer complications was 0.76% with celecoxib and 1.45% for ibuprofen or diclofenac. The less substantial reduction in events in the CLASS study compared with the VIGOR may be due, at least in part, to the fact that 21% of the patients were also on low dose aspirin. However it is premature to say that the benefit of Cox-2 inhibitors is lost in patients taking aspirin. There is continuing debate on the role of Cox-2 inhibitors in patients who have other risk factors for complicated ulcer disease e.g. patients who are elderly, on aspirin or corticosteroids, have a previous ulcer or have H. pylori infection.
Export Options
About this article
Cite this article as:
Hawkey J. C. and Skelly M. M., Gastrointestinal Safety of Selective COX-2 Inhibitors, Current Pharmaceutical Design 2002; 8 (12) . https://dx.doi.org/10.2174/1381612023394999
DOI https://dx.doi.org/10.2174/1381612023394999 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Neuropathic Pain: Models and Mechanisms
Current Pharmaceutical Design Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Modulation of Proinflammatory Bacteria- and Lipid-Coupled Intracellular Signaling Pathways in a Transwell Triple Co-Culture Model by Commensal Bifidobacterium Animalis R101-8
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry PREFACE [Hot topic: Molecules of Infectious Agents as Immunomodulatory Drugs (Guest Editor: William Harnett)]
Current Topics in Medicinal Chemistry Synthesis of Ethyl 4-O-[4-(1,2,4-Oxadiazol-5-yl)phenyl]-α-D-mannopyranosides
Letters in Organic Chemistry Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors
Current Pharmaceutical Biotechnology Motility Disorders, Functional Gastrointestinal Disorders, Inflammatory Bowel Disease and Cardiac Rhythm Disturbances - Is there a Link? Review of Literature
Current Drug Targets F2-Isoprostanes: Review of Analytical Methods
Current Pharmaceutical Analysis Non-Hodgkins Lymphoma: Review of Conventional Treatments
Current Pharmaceutical Biotechnology Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Plant Antimicrobial Peptides: An Overview of SuperSAGE Transcriptional Profile and a Functional Review
Current Protein & Peptide Science CYP2C and CYP2B Mediated Metabolic Activation of Retrorsine in Cyp3a Knockout Mice
Current Drug Metabolism Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets